Your browser doesn't support javascript.
loading
Erectile dysfunction in men treated for testicular cancer.
Tal, Raanan; Stember, Doron S; Logmanieh, Nina; Narus, Joseph; Mulhall, John P.
Affiliation
  • Tal R; Male Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
BJU Int ; 113(6): 907-10, 2014 Jun.
Article in En | MEDLINE | ID: mdl-24053222
ABSTRACT

OBJECTIVE:

To study the unique characteristics of erectile dysfunction (ED) in a population of men who developed ED after testicular cancer (TC) diagnosis and treatment. PATIENTS AND

METHODS:

All men treated for TC who presented for sexual function evaluation were included in an institutional database. All men underwent standard evaluation including a history/physical examination, completion of the International Index of Erectile Function (IIEF) questionnaire, testosterone/gonadotropin measurement and penile duplex Doppler ultrasonography (DUS).

RESULTS:

The study population comprised 76 men whose mean (SD) age was 29 (8) years and of whom 25% were married/had a partner. In all, 39% of the patients had seminoma and 61% had non-seminomatous germ-cell tumour (NSGCT). A total of 66% of patients with seminoma underwent radiation therapy. Of the patients with NSGCT, 79% received chemotherapy, 18% underwent primary retroperitoneal lymph node dissection (RPLND) and 20% underwent post-chemotherapy RPLND. The mean (SD) time before seeking sexual medicine consultation was 12 (7) months after treatment completion, the median (range) number of vascular risk factors was 0 (0-2) and the mean (SD) remaining testis volume was 16 (8) mL. Mean (SD) total testosterone, luteinizing hormone, follicle-stimulating hormone levels were 312 (186) ng/dL, 9 (7) IU/mL, 17 (12) IU/mL. A total of 26% of patients had total testosterone levels <300 ng/dL. In all, 84% of patients complained primarily of loss of erection-sustaining capability and 24% had episodes of transient ED before TC diagnosis. The mean (SD) IIEF erectile function domain score was 16 (7). All the patients (100%) had a normal DUS. Mean (SD) peak systolic and end-diastolic velocities were 48 (16) and 1.2 (2.2) cm/s, respectively. A total of 88% of patients responded to phosphodiesterase type 5 inhibitor (PDE5i) use with erections sufficient for penetration, but 12% did not (mean [SD] erectile function domain score 27 [5] vs 17 [6]). There were no differences in haemodynamics between those men with and without hypogonadism.

CONCLUSIONS:

Men with TC presenting with ED after treatment appear uniformly to have normal erectile haemodynamics, suggesting adrenaline-mediated ED. While the majority of TC survivors with ED respond successfully to PDE5i, a significant minority do not.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Testicular Neoplasms / Neoplasms, Germ Cell and Embryonal / Erectile Dysfunction Type of study: Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Year: 2014 Type: Article

Full text: 1 Database: MEDLINE Main subject: Testicular Neoplasms / Neoplasms, Germ Cell and Embryonal / Erectile Dysfunction Type of study: Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Year: 2014 Type: Article